Advanced or recurrent gastric cancer overexpressing HER2, not amenable to curative resection
Conditions
Interventions
investigational material(s)
Generic name etc : TRASTUZUMAB BS FOR INTRAVENOUS DRIP INFUSIONS 'DAIICHI SANKYO'(Trastuzumab (Genetical Recombination)[Trastuzumab Biosimilar 2])
INN of investigational ma
Sponsors
DAIICHI SANKYO CO., LTD
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients with advanced or recurrent gastric cancer overexpressing HER2, not amenable to curative resection 2.Patients administered TRASTUZUMAB BS for the first time (patients with a history of administration of the original biological product and patients with a history of administration of other trastuzumab biosimilar can also be registered) 3.Patients who started administration of TRASTUZUMAB BS during the contract period (contract period based on the contract with each medical site) 4.Patients who started administration of TRASTUZUMAB BS during the registration period 5.Patients from whom written informed consent was obtained
Exclusion criteria
Exclusion criteria: Patients who do not meet eligibility criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| efficacy Best Overall Response | — |
Secondary
| Measure | Time frame |
|---|---|
| other - | — |
Countries
Japan
Contacts
Public ContactGPSP Contact
GPSP for Contact
Outcome results
None listed